Table 1.

Characteristics of Study Participants

Participant	Age	Gender	Race	SARS-CoV-2 Vaccine	Plasma Viremia (Copies/mL)		CD4+ T-Cell Count (Cells/mm3)		CD8+ T-Cell Count (Cells/mm3)
					Preboost	Postboost	Preboost	Postboost	Preboost	Postboost
1	55	Male	White	Moderna	<40	<40	860	800	1131	860
2	27	Female	Hispanic	Moderna	<40	<40	1526	1323	604	540
3	43	Male	Hispanic	Moderna	<40	<40	NA	949	NA	401
4	40	Male	Hispanic	Pfizer-BioNTech	<40	<40	NA	597	NA	522
5	49	Male	Hispanic	Pfizer-BioNTech	<40	<40	443	655	335	384
6	53	Male	Black	Moderna	<40	<40	503	576	444	484
7	49	Male	Hispanic	Moderna	108	<40	617	902	341	442
8	34	Male	Hispanic	Moderna	<40	<40	852	785	710	981
9	31	Male	Mixed	Pfizer-BioNTech	<40	<40	307	383	613	689

Abbreviations: NA, not available; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.